0600: Correlates Between Rheumatoid Arthritis Clinical Factors and Synovial Cell Phenotypes: Data from the Accelerated Medicines Partnership

Dana Weisenfeld¹, Fan Zhang², Laura Donlin³, Anna Jonsson¹, William Apruzzese¹, Debbie Campbell⁴, Ellen Gravallese⁵, Larry Moreland⁶, Susan Goodman³, Michael Brenner⁵, Soumya Raychaudhuri¹, Andrew Filer⁷, Jennifer Anolik⁸, Vivian Bykerk³ and Katherine Liao¹, ¹Brigham and Women's Hospital, Boston, MA, ²University of Colorado, Aurora, CO, ³Hospital for Special Surgery, New York, NY, ⁴University of Rochester, Rochester, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶University of Colorado, Denver, CO, ⁷University of Birmingham, Birmingham, United Kingdom, ⁸University of Rochester Medical Center, Rochester, NY

Background/Purpose: Prior studies have characterized the diverse cell types in the RA synovium through a multi-center consortium incorporating RNA-seq data. Due to the novelty of this approach, there are limited data on the associations between cell types and states with patient level clinical measurements. Using the largest cohort to date with clinical and multi-cell type data, the objective of this study was to determine associations between RA clinical factors and cell types at the patient level.

Methods: AMP RA recruited patients from 13 centers with inclusion criteria as previously described¹. Briefly, subjects were age≥18, fulfilled the 1987 or 2010 ACR/EULAR RA Classification criteria with ≥2 tender and swollen joints and CDAI≥10. Subjects were additionally selected based on treatment status: (i) DMARD naïve, (ii) methotrexate (MTX) inadequate, (iii) TNFi inadequate responders. Demographics, RA treatments at baseline (no DMARD, nbDMARD/no bDMARD, any bDMARD), and RA clinical factors, ESR, CRP, were assessed; CDAI and DAS28-CRP were calculated. Biopsies were performed on an inflamed joint and tissue were processed as previously described to determine synovial cellular phenotype to obtain cell type % and cell type abundance phenotype (CTAP)¹. The 6 CTAPs identified named by the dominant cell type were: (1) endothelial, fibroblast, and myeloid cells (EFM), (2) fibroblasts (F), (3) myeloid, (4) T- and B-cells (TB), (5) T cells and fibroblasts (TF), (6) T and myeloid cells (TM. We performed correlations between key RA clinical data (Figure 1) and cell type % using Spearman's correlation for continuous variables and point bi-seral for binary variables. Chi square or ANOVA were performed to test differences in means or proportions, respectively across CTAP categories. In this discovery cohort, we focused on associations p< 0.01, and reported p< 0.05.

Results: We studied n=105 subjects, mean age 56 years, 74% female, 70% White, 15% Black, 31% Hispanic; 85% were seropositive, mean RA duration 6.6 years, DAS28-CRP3 4.8, and hsCRP 18.1mg/L. Anti-CCP and RF positivity correlated with low % myeloid cells, while RF+ was correlated with high % T-cells (Figure 1). Higher DAS28-CRP was correlated with higher % T cells in the synovium. Across CTAPs, the TF cluster had the highest HAQ and patient global scores (Table 2). When examining variation across treatments, subjects on MTX or other nbDMARDs alone had higher %B-cells than other groups. For subjects on bDMARDs, the majority belonged to the EFM CTAP (57%), while none were categorized as TF. No significant difference was observed across CTAPs for age, sex, RA disease duration, DAS28-CRP, and hsCRP.

Conclusion: In this comprehensive screen of clinical factors measured at the time of synovial biopsy, we observed differential associations between cell phenotypes with bDMARD vs nbDMARD use, suggesting that RA therapies may impact cell composition in the synovium. Future directions include longitudinal studies of treatment response to determine whether cell phenotypes can improve our ability to select the optimal RA treatment for each patient.

¹Zhang, Jonsson, et al., bioRxiv 2022.02.25.481990
Figure 1. Correlations between cell type % with clinical factors; p-value < 0.01 in green, p≥0.01 and < 0.05 in blue.


Disclosures: D. Weisenfeld, None; F. Zhang, None; L. Donlin, None; A. Jonsson, Amgen; W. Apruzzese, None; D. Campbell, None; E. Gravallese, New England Journal of Medicine, Textbook Rheumatology, AMN healthcare, CVS, American Well Corporation, Cerner Corp; L. Moreland, None; S. Goodman, Novartis, UCB; M. Brenner, GSK, 4FO Ventures, Mestag Therapeutics; S. Raychaudhuri, Mestag, Inc, Rheos Medicines, Janssen, Pfizer, Biogen; A. Filer, None; J. Anolik, None; V. Bykerk, Amgen, Bristol-Myers Squibb(BMS), Genzyme, Brainstorm, Gilead, Regeneron, UCB, Pfizer, Sanofi, Aventis; K. Liao, None.